Interleukin 11 (IL-11): Role(s) in Breast Cancer Bone Metastases
Open Access
- 8 June 2021
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 9 (6) , 659
Abstract
Bone metastases represent the main problem related to the progression of breast cancer, as they are the main cause of death for these patients. Unfortunately, to date, bone metastases are incurable and represent the main challenge for the researcher. Chemokines and cytokines affect different stages of the metastatic process, and in bone metastases, interleukin (IL) -6, IL-8, IL-1β, and IL-11 participate in the interaction between cancer cells and bone cells. This review focuses on IL-11, a pleiotropic cytokine that, in addition to its well-known effects on several tissues, also mediates certain signals in cancer cells. In particular, as IL-11 works on bone remodeling, it plays a relevant role in the osteolytic vicious cycle of bone resorption and tumour growth, which characterizes bone metastasis. IL-11 appears as a candidate for anti-metastatic therapy. Even if different therapeutic approaches have considered IL-11 and the downstream-activated gp130 signaling pathways activated downstream of gp130, further studies are needed to decipher the contribution of the different cytokines and their mechanisms of action in breast cancer progression to define therapeutic strategies.Keywords
This publication has 121 references indexed in Scilit:
- Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cellsJournal of Clinical Investigation, 2013
- mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in miceJournal of Clinical Investigation, 2013
- IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cellsBMC Cancer, 2013
- Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcomeBMC Cancer, 2013
- Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis InitiationCancer Cell, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in miceJournal of Clinical Investigation, 2010
- IL11 Antagonist Inhibits Uterine Stromal Differentiation, Causing Pregnancy Failure in Mice1Biology of Reproduction, 2009
- Endogenous IL-11 Signaling Is Essential in Th2- and IL-13–Induced Inflammation and Mucus ProductionAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastasesProceedings of the National Academy of Sciences, 2006